Table 3 Univariate relationship of characteristics of patients with rheumatoid arthritis with carotid intima-media thickness and carotid plaques
Carotid plaque | CIMT (×10 mm) | |||
|---|---|---|---|---|
Patients with RA (n = 178) | OR (95% CI) | p Value | β Coefficient (95% CI) | p Value |
Age | 1.15 (1.10–1.20) | 0.000 | 0.08 (0.01–0.01) | 0.000 |
Male sex | 3.00 (1.44–6.26) | 0.003 | 1.1 (0.6–1.6) | 0.000 |
Body mass index | 1.00 (0.95–1.06) | 0.92 | 0.03 (0.02–0.07) | 0.23 |
Abdominal circumference | 1.01 (0.99–1.04) | 0.31 | 0.02 (0.00–0.03) | 0.021 |
Systolic blood pressure | 1.04 (1.02–1.06) | 0.000 | 0.04 (0.03–0.05) | 0.000 |
Diastolic blood pressure | 1.02 (0.997–1.05) | 0.078 | 0.02 (0.01–0.04) | 0.009 |
Cardiovascular comorbidity | ||||
Smoking | 1.04 (0.46–2.37) | 0.92 | −0.1 (0.7 to 0.4) | 0.63 |
Diabetes | 3.54 (1.51–8.30) | 0.004 | 1.0 (0.04 to 1.6) | 0.001 |
Hypertension | 2.57 (1.36–4.87) | 0.004 | 0.6 (0.2 to 1.1) | 0.005 |
Dyslipidemia | 3.61 (1.91–6.84) | 0.000 | 0.4 (−0.01 to 0.8) | 0.082 |
Antihypertensive treatment | 2.73 (1.44–5.18) | 0.002 | 0.7 (0.2 to 1.1) | 0.002 |
Statins | 3.93 (2.04–7.58) | 0.000 | 0.5 (0.0 to 0.9) | 0.036 |
Laboratory including lipid profile | ||||
ESR | 1.02 (1.01–1.04) | 0.003 | 0.01 (0.00 to 0.02) | 0.041 |
CRP | 0.45 (0.96–1.02) | 0.45 | 0.00 (−0.01 to 0.01) | 0.947 |
Cholesterol | 1.00 (0.99–1.01) | 0.83 | 0.00 (0.00 to 0.01) | 0.16 |
Triglycerides | 1.00 (0.99–1.01) | 0.13 | 0.00 (0.00 to 0.00) | 0.034 |
HDL cholesterol | 0.99 (0.98–1.01) | 0.51 | −0.01 (−0.03 to 0.00) | 0.034 |
LDL cholesterol | 0.99 (0.99–1.01) | 0.77 | 0.00 (0.00 to 0.01) | 0.14 |
Lipoprotein A | 1.00 (1.00–1.01) | 0.043 | 0.00 (0.00 to 0.00) | 0.76 |
Apolipoprotein A | 1.01 (0.99–1.02) | 0.37 | 0.00 (−0.01 to 0.01) | 0.80 |
Apolipoprotein B | 0.99 (0.99–1.01) | 0.73 | 0.00 (0.00 to 0.00) | 0.48 |
ApoB/ApoA ratio | 0.70 (0.21–2.33) | 0.56 | 0.4 (0.4 to 1.1) | 0.36 |
Atherogenic index | 1.06 (0.87–1.29) | 0.57 | 0.2 (0.0 to 0.3) | 0.029 |
Rheumatoid arthritis-related data | ||||
Disease duration | 1.02 (0.99–1.06) | 0.17 | 0.01 (−0.01 to 0.03) | 0.41 |
DAS28 | 1.36 (1.05–1.77) | 0.022 | 0.12 (−0.06 to 0.30) | 0.18 |
DAS28-CRP | 1.19 (0.88–1.63) | 0.26 | 0.08 (−0.14 to 0.29) | 0.47 |
SDAI | 0.99 (0.98–1.02) | 0.85 | 0.00 (−0.01 to 0.01) | 0.76 |
CDAI | 1.01 (1.00–1.01) | 0.055 | 0.00 (0.00 to 0.01) | 0.16 |
Rheumatoid factor | 0.87 (0.45–1.71) | 0.69 | −0.5 (−1.0 to 0.0) | 0.043 |
ACPA | 0.87 (0.46–1.63) | 0.66 | −0.3 (−0.8 to 0.1) | 0.14 |
Prednisone intake | 1.11 (0.59–2.10) | 0.74 | 0.0 (−0.4 to 0.5) | 0.90 |
Prednisone doses | 0.99 (0.89–1.09) | 0.81 | −0.04 (−0.1 to 0.2) | 0.20 |
NSAIDs | 0.40 (0.21–0.76) | 0.005 | −0.6 (−1.0 to 0.2) | 0.005 |
DMARDs | 2.04 (0.77–5.41) | 0.15 | 0.3 (−0.4 to 0.9) | 0.43 |
Methotrexate | 0.77 (0.38–1.54) | 0.46 | −0.3 (−0.8 to 0.2) | 0.25 |
Leflunomide | 2.04 (0.78–5.32) | 0.14 | 0.9 (0.2 to 1.6) | 0.010 |
Biologic therapy | 0.51 (0.23–1.13) | 0.098 | −0.2 (−0.8 to 0.3) | 0.35 |
Anti-TNF-α therapy | 0.89 (0.36–2.23) | 0.81 | 0.4 (−0.3 to 1.0) | 0.23 |
Tocilizumab | 0.16 (0.02–1.26) | 0.081 | −0.7 (−1.6 to 0.1) | 0.085 |
Rituximab | 0.42 (0.05–3.80) | 0.44 | −1.1 (−2.4 to 0.1) | 0.81 |
Abatacept | 1.71 (0.11–27.8) | 0.71 | 0.6 (−1.4 to 2.6) | 0.55 |